Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand
Background: Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods: Children aged <18 years initiating combination ART (≥2 nucle...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Clinical infectious diseases
Year: 2017, Jahrgang: 66, Heft: 4, Pages: 594-603 |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/cix854 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1093/cid/cix854 Verlag, Volltext: https://academic.oup.com/cid/article/66/4/594/4237699 
|
| Verfasserangaben: | The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 167847150X | ||
| 003 | DE-627 | ||
| 005 | 20230426135240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191008r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/cix854 |2 doi | |
| 035 | |a (DE-627)167847150X | ||
| 035 | |a (DE-599)KXP167847150X | ||
| 035 | |a (OCoLC)1341244952 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Goetghebuer, Tessa |e VerfasserIn |0 (DE-588)1196639736 |0 (DE-627)1678469777 |4 aut | |
| 245 | 1 | 0 | |a Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand |c The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord |
| 264 | 1 | |c 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.10.2019 | ||
| 500 | |a The members of the project team and writing group are listed in the notes | ||
| 500 | |a Published online September 26, 2017 | ||
| 520 | |a Background: Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand. Methods: Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks. Results: Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch. Conclusions: One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch. | ||
| 534 | |c 2017 | ||
| 700 | 1 | |a Buchholz, Bernd |d 1960- |e VerfasserIn |0 (DE-588)1069569372 |0 (DE-627)822025116 |0 (DE-576)429275161 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases |d Oxford : Oxford Journals, 1992 |g 66(2018), 4, Seite 594-603 |h Online-Ressource |w (DE-627)320418308 |w (DE-600)2002229-3 |w (DE-576)090881834 |x 1537-6591 |7 nnas |a Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand |
| 773 | 1 | 8 | |g volume:66 |g year:2018 |g number:4 |g pages:594-603 |g extent:10 |a Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/cix854 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/cid/article/66/4/594/4237699 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191008 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1069569372 |a Buchholz, Bernd |m 1069569372:Buchholz, Bernd |d 60000 |e 60000PB1069569372 |k 0/60000/ |p 48 | ||
| 999 | |a KXP-PPN167847150X |e 3520172100 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"320418308","language":["eng"],"note":["Gesehen am 31.07.2023"],"disp":"Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and ThailandClinical infectious diseases","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"year":"2018","pages":"594-603","issue":"4","text":"66(2018), 4, Seite 594-603","volume":"66","extent":"10"},"pubHistory":["14.1992 -"],"title":[{"title_sort":"Clinical infectious diseases","subtitle":"electronic edition","title":"Clinical infectious diseases"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1537-6591"],"eki":["320418308"],"zdb":["2002229-3"]},"origin":[{"publisherPlace":"Oxford ; Chicago, Ill.","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Oxford Journals ; Univ. of Chicago Press, Journals Division"}]}],"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord"]},"id":{"eki":["167847150X"],"doi":["10.1093/cid/cix854"]},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"language":["eng"],"recId":"167847150X","note":["Gesehen am 08.10.2019","The members of the project team and writing group are listed in the notes","Published online September 26, 2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"roleDisplay":"VerfasserIn","display":"Goetghebuer, Tessa","role":"aut","family":"Goetghebuer","given":"Tessa"},{"given":"Bernd","family":"Buchholz","role":"aut","display":"Buchholz, Bernd","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand","title":"Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand"}]} | ||
| SRT | |a GOETGHEBUETIMETOSWIT2018 | ||